Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

Title: A Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors Abstract Number: 1189 Presenter: Justin Moser, M.D., HonorHealth Research Institute Presentation Time: Saturday, November 7, 2026; 2:30-2:45 p.m. MT Location: North Building - 300 Level – Halls BC Session 205: Clinical Oral Abstract Session 2, 1:30-3:00 p.m. MT Session Schedule: https://www.sitcancer.org/2026/schedule/sitc-2026-schedule#session-1643